Browse by ▼

Novartis

  • Is There Growth Left in Massive Drug Stocks?

    By Chris Hodge - May 22, 2013 | Tickers: JNJ, NVS, PFE

    In an already massive market segment, are dividends all you can hope for when you hunt down "elephants" like Warren Buffett does? While you probably won't get a five-bagger at this level, seeing a price increase in the 20%-50% range is very possible. In the case of stock splits, you may very well see adjusted share prices rise considerably. Plus, there's always the prospect of a company more »

  • Santarus Is a Real Gas!

    By Doug Lofton - May 21, 2013 | Tickers: AZN, AZN, NVS, SNTS

    Investing in the stock market can sometimes be a gut wrenching experience. However, for investors in Santarus (NASDAQ: SNTS), a pain in the gut can translate into big profits!

    Santarus is a bio-pharmaceutical company that produces and commercializes proprietary pharmaceutical products that address the needs of patients treated by gastroenterologists, endocrinologists, and other physician specialists.

    The following are three significant developments over the past year that collectively make Santarus a more »

  • Flush With Cash, Elan Goes on a Buying Spree

    By Diane Alter - May 20, 2013 | Tickers: BIIB, ELN, NVS

    Call it the luck of the Irish.

    Prospects have been glum for Elan Corp (NYSE: ELN), but the Irish pharmaceutical company is showing some real promise.

    After suffering a serious setback last July, when results for bapineuzumab, an Alzheimer’s therapy in development with Pfizer and Johnson & Johnson, were disappointing, many questioned its survival as a stand alone company. 

    You see, the failure of that drug left Elan with just more »

  • 6 Big Pharma Stocks With Lower Credit Risk Than U.S. Treasuries: Part II

    By Meena Krishnamsetty - May 10, 2013 | Tickers: MRK, NVS, PFE

    The healthcare sector has been known for paying dependable dividends and producing strong total returns over time. Among the major pharmaceutical companies, there are a few that stand out as most financially sound, as reflected by their CDS spreads below those of the U.S. Treasuries.

    This is the second part of our list; the first section included Bristol Myers Squibb, Eli Lilly, and Johnson & Johnson.

    Why use CDS spreads more »

  • Should We Get Bullish on This Fast Growing Healthcare Company?

    By Anh HOANG - May 10, 2013 | Tickers: AGN, JNJ, NVS

    Allergan (NYSE: AGN) has been consistently increasing on the market since the market bottom, from nearly $32 per share in November 2008 to more than $116 per share in the middle of April 2013. However, Allergan has experienced a lot of recent volatilty, and now is near $105. The company is in the portfolio of several successful investors including Joel Greenblatt and Jim Simons. Should investors consider Allergan at its more »

  • Will $15 Billion Work for This Troubled Drug Maker?

    By Nick Chiu - May 9, 2013 | Tickers: MRK, NVS, PFE

    Merck (NYSE: MRK), with a market cap of $138.09 billion, is a global health care company, delivering innovative health solutions through its prescription medicines, vaccines, and biologic therapies, etc.

    Merck does not look good in the near-term with its disappointing revenue and profit that are below analysts’ estimates. Despite the previous downplay, the result still surprised to the down side due to strong generic competitions and unfavorable exchange rates more »

  • Did This Stock Deserve This Sudden Upward Swing?

    By Jeremiah Feliciano - May 8, 2013 | Tickers: MNKD, NVS, VRTX

    Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged from $52.87 on April 18 to a 12-year high of $85.90 per share on April 19 after the company reported positive outcomes from the Phase II clinical trial of its experimental drug, VX-661. Last time the stock witnessed such as rapid growth was on November 3, 2000, when the prices reached $93.87 a share.

    It’s only Phase II

    The drug more »

  • I Would Buy a Generic Drug ETF, If One Existed

    By Seth Robey - May 2, 2013 | Tickers: BBH, IBB, NVS, XBI, TEVA | Editor's Choice

    About 120 drugs have lost or will lose patent protection in 2013.  EvaluatePharma estimates that this accounts for nearly $29 billion in total annual revenue, a number which will grow ten-fold between now and 2018.  As big biotech and big pharma dive head-first off the patent cliff, there is suddenly an expanding market for cheap generic versions of blockbuster drugs of the past.  Investors looking to profit from growing sales more »

  • Novartis’ Patent Loss Underscores Future Growth Dangers

    By Peter Pham - May 1, 2013 | Tickers: MRK, NVS, PFE

    In a much hyped and landmark case, Novartis (NYSE: NVS) has had its patent revoked by Indian authorities. Authorities made it clear that India can step forward to revoke drug patents in the occurrence of any serious disease or pandemics.

    The Supreme Court’s ruling on on April 1st came as a blow to Novartis rejecting the patent application of its cancer drug Glivec. This was one of a more »

  • Big Pharma's Kickback Conundrum

    By Leo Sun - May 1, 2013 | Tickers: GSK, NVS, PFE

    Big pharma is a controversial industry. Along with tobacco companies, they are some of the most vilified businesses in the world. On one hand, large pharmaceutical companies invest heavily in producing breakthrough medicines. Since 2000, the 31 main companies of the sector spent a combined $550 billion on research & development, creating 400 new medicines in the process.

    On the other hand, these companies have attempted to stop generic versions of more »

  • 3 Misunderstood Large Cap Value Finds

    By Reuben Brewer - April 30, 2013 | Tickers: INTC, NVS, VOD

    Perkins Large Cap Value Fund (JNPLX) looks for temporarily misunderstood companies. Intel (NASDAQ: INTC), Vodafone (NASDAQ: VOD), and Novartis (NYSE: NVS) fit the bill.

    Out of Favor

    As the fund's name suggests, it focuses on large cap value stocks. In general, management seeks out companies with strong balance sheets, solid recurring free cash flows, attractive valuations, and favorable risk/reward characteristics. All of that's expected.

    One area of more »

  • Investing in Potential Blockbusters

    By Shweta Dubey - April 19, 2013 | Tickers: JNJ, NVS, SNY

    A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug. To create a blockbuster drug is a big achievement for any pharmaceutical company- both financially and operationally. In this article, I have discussed three drug manufacturers that are known for producing such drugs in the past. Let's see what future blockbusters they have in their portfolios:

    Sanofi (NYSE: SNY)

    The more »

  • Investing in Potential Blockbusters

    By Shweta Dubey - April 6, 2013 | Tickers: JNJ, NVS, SNY

    A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug. To create a blockbuster drug is a big achievement for any pharmaceutical company- both financially and operationally. In this article, I have discussed three drug manufacturers that are known for producing such drugs in the past. Let's see what future blockbusters they have in their portfolios:

    Sanofi (NYSE: SNY)

    The more »

  • Investing in Potential Blockbusters

    By Shweta Dubey - April 6, 2013 | Tickers: JNJ, NVS, SNY

    A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug. To create a blockbuster drug is a big achievement for any pharmaceutical company- both financially and operationally. In this article, I have discussed three drug manufacturers that are known for producing such drugs in the past. Let's see what future blockbusters they have in their portfolios:

    Sanofi (NYSE: SNY)

    The more »

  • Want to do Blockbuster Investing?

    By Shweta Dubey - April 3, 2013 | Tickers: JNJ, NVS, SNY

    A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug. To create a blockbuster drug is a big achievement for any pharmaceutical company- both financially and operationally. In this article, I have discussed three drug manufacturers that are known for producing such drugs in the past. Let's see what future blockbusters they have in their portfolios:

    Sanofi (NYSE: SNY)

    The more »

  • Could Novartis Decision Bring Pharma Sector Rotation?

    By Dana Blankenhorn - April 2, 2013 | Tickers: ACT, NVS

    One of the best places to be fully invested these days is pharmaceuticals.

    Over the last year the biggest drug makers, like Pfizer, Johnson & Johnson, and Novartis (NYSE: NVS), which trades as an ADR here, are all up sharply. Novartis is up over 30%.

    But to hear the company's PR tell it, the company is about to go down hard. The company is upset that it lost an appeal more »

  • These European Pharmaceuticals Show Promise

    By Robert Ciura - March 27, 2013 | Tickers: AZN, NVS, SNY

    Companies in the health care sector provide essentials to both customers and investors: namely their products and their dividends. It’s safe to assume that people need to take their medicines, no matter the prevailing economic climate.

    When most investors think of big pharma, they’d likely come up with the usual suspects. While the U.S-based health care giants are well-known to most investors and worthy of investor consideration more »

  • Top # 10: International Companies (ADRs)

    By Rohit Gupta - March 18, 2013 | Tickers: BUD, AZN, GSK, NVS, NVO, SNY

    A list of Top 10 International companies, with ADRs (American Deposittory Receipts) listed in the US. While all large international brands – a synopsis of their unique competitive advantage and long term moat

    1. Anheuser-Busch (NYSE: BUD) : juggernaut in the global beer market with leadership position in four of the top five beer profit pools (United States, Canada, Brazil, and Mexico). Further, strength of ABI's focus brands (Budweiser, Stella Artois more »

  • This Defensive Growth Favorite Updates Guidance

    By Lee Samaha - March 15, 2013 | Tickers: JNJ, NVS, COO

    Editor's Note: This post has been updated to reflect the correct stock symbol for Novartis.

    Anyone looking for a defensive growth stock for their portfolio should at least add Cooper Companies (NYSE: COO) to their monitor list. If you are underwhelmed by my intro then I have had the desired effect! This is a great company and it has lots of upside drivers to its earnings forecasts but it more »

  • Put some DRUGS into your portfolio.

    By bishwanath baheti - March 11, 2013 | Tickers: ABBV, NVS

    Whenever you have a little bit of fever or headache,what do you do???

    You rush to nearest chemist or a Doc n get some drugs.That’s the general situation presently we are facing in our fast moving lives.

    What request do we make to our Doc?

    Yes we do!!!....We do request him to give us some kind of strong medicine so that we may recover back as more »

  • Page 1 of 5